Hennion & Walsh Asset Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.68M Buy
10,630
+42
+0.4% +$5.68K 0.05% 429
2026
Q1
$1.35M Sell
10,588
-1,221
-10% -$152K 0.05% 440
2025
Q4
$1.44M Sell
11,809
-116
-1% -$13.3K 0.05% 427
2025
Q3
$1.19M Buy
11,925
+2
+0% +$180 0.04% 471
2025
Q2
$989K Buy
11,923
+142
+1% +$11.3K 0.04% 497
2025
Q1
$955K Buy
11,781
+7,391
+168% +$661K 0.04% 485
2024
Q4
$639K Hold
4,390
0.03% 571
2024
Q3
$662K Hold
4,390
0.03% 553
2024
Q2
$612K Hold
4,390
0.03% 532
2024
Q1
$617K Buy
4,390
+2,035
+86% +$189K 0.03% 524
2023
Q4
$210K Buy
+2,355
New +$175K 0.01% 765

Other funds holding XBI

Hennion & Walsh Asset Management's XBI Position: Q2 2026 in Review

Hennion & Walsh Asset Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 0.4% in Q2 2026, buying an estimated $5.68K and bringing the position to 10,630 shares worth $1.68M. The position accounts for 0.05% of the portfolio, ranked #429.

Hennion & Walsh Asset Management first reported a position in XBI in Q4 2023 and has held it in 11 quarters since. 251 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

  • Hennion & Walsh Asset Management held 10,630 shares of State Street SPDR S&P Biotech ETF worth $1.68M as of Q2 2026.
  • Hennion & Walsh Asset Management bought 42 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $5.68K.
  • State Street SPDR S&P Biotech ETF made up 0.05% of Hennion & Walsh Asset Management's portfolio in Q2 2026, its #429 holding.
  • Hennion & Walsh Asset Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2023 and has held it in 11 quarters since.
  • 251 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.